AKASA vs Arintra
Two Autonomous Medical Coding vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| AKASA | Arintra | |
|---|---|---|
| Pricing model | Enterprise contract (custom) · Subscription sized by transaction volume | Not published · Custom quotes |
| Speed to go live | 60-90 days typical; longer multi-facility | Native via Epic Toolbox and athenahealth Marketplace |
| Automation model | Autonomous agents · GenAI automation with human review | Autonomous agents · direct-to-bill autonomous coding |
| Built for | Mid-size groups, Enterprise systems | Mid-size groups, Enterprise systems |
| Security posture | HITRUST, SOC 2 Type II, HIPAA | HITRUST, HIPAA |
| Company maturity | 8 yrs (est. 2018) | 6 yrs (est. 2020) |
| Financial backing | $205M · Series B | $21.5M · Series A |
| Named customers | 2 named | 2 named |
| Published results | Specific numbers public | Specific numbers public |
| Documented integrations | 3 listed | 2 listed |
| Third-party validation | None found | None found |
Bottom line
- Pick AKASA if you run a mid-size or large health system, ideally on Epic, and want generative AI working claims, auths, and coding in-house instead of outsourcing staff.
- Pick Arintra if you code high volumes in Epic or athenahealth and want autonomous coding without changing clinician workflow.
AKASA
Generative AI for coding and revenue cycle operations
- Founded
- 2018
- HQ
- South San Francisco, CA
- Stage
- Series B
- Raised
- $205M
What it does
- Generative AI medical coding trained on clinical documentation
- Clinical documentation integrity (CDI) review at scale
- Automates prior auth status and claims follow-up work
- LLMs fine-tuned on customer clinical and financial data
- Surfaces missed codes and documentation gaps pre-bill
Where it's strong
- Cleveland Clinic co-developed and is now deploying its GenAI CDI product across all US locations, a rare tier-one clinical validation.
- Deep pockets ($205M raised) and deployment across 650+ hospitals reduce vendor-viability risk.
- Focus on mid-revenue-cycle (coding plus CDI) fits health systems that want one vendor for both.
What buyers should weigh
- The company pivoted from RPA-style automation to generative AI, so ask which product generation you are actually buying.
- Flagship proof points are large academic systems; fit and pricing for smaller hospitals is less proven.
- Last disclosed raise was 2022, so probe current burn and roadmap funding.
Named customers
Cleveland Clinic · Duke University Health System
Integrations
Arintra
Autonomous medical coding that runs inside your EHR
- Founded
- 2020
- HQ
- Austin, TX
- Stage
- Series A
- Raised
- $21.5M
What it does
- Fully autonomous coding from clinical documentation
- Works inside Epic and athenahealth, no workflow change
- Denial reduction and revenue capture on automated claims
- Coding audit trails and compliance documentation
- Specialty coverage across outpatient service lines
Where it's strong
- Published customer results are specific and strong: 5.1% revenue lift and 43% fewer denials on automated claims at Mercyhealth.
- Direct-to-billing autonomy rather than coder-assist, which is where the cost savings actually are.
- In-EHR operation means no new workqueue tool for HIM teams to learn.
What buyers should weigh
- Small named customer list so far; ask for references in your specialty mix and payer mix.
- A Series A vendor carries more long-term viability risk than Solventum or Optum for a core RCM function.
- Verify coverage for your setting; published wins skew toward outpatient and professional coding.
Named customers
Mercyhealth · Reid Health
Integrations
Compare against the rest of Autonomous Medical Coding
Deciding between these two?
First Pass tracks Autonomous Medical Coding every week: funding, launches, and what changed since this page was written.